Evidence map›Paper›PMID 38243949›Full record

ArticleAnti-cancer agents in medicinal chemistry2024

Preparation, Characterization, and Anticancer Activity Assessment of Chitosan/TPP Nanoparticles Loaded with

Maral Mahboubi Kancha, Mohsen Mehrabi, Fatemeh Sadat Bitaraf, Hamid Vahedi, Morteza Alizadeh, Andreas Bernkop-Schnürch

Abstract read
PubMed Publisher
In one paragraph

Article in Anti-cancer agents in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Maral Mahboubi KanchaStudent Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
Mohsen MehrabiDepartment of Medical Nanotechnology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
Fatemeh Sadat BitarafDepartment of Medical Biotechnology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
Hamid VahediDepartment of Gastroenterology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
Morteza AlizadehDepartment of Tissue Engineering, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
Andreas Bernkop-SchnürchDepartment of Pharmaceutical Technology, University of Innsbruck, Institute of Pharmacy, Center for Chemistry and Biomedicine, 6020, Innsbruck, Austria.
Shahroud University of Medical Sciences · IRUniversität Innsbruck · AT

Funding

Shahroud University of Medical Sciences, Shahroud, Iran Grant number 14010037
6 · The paper itself

Abstract

AIMS AND

background

objectiveNanotechnology-based drug delivery systems are suitable for protecting

methodsIn the present study, chitosan nanoparticles were prepared using the ionotropic gelation method with emulsion cross-linking. The venom's encapsulation efficiency, loading capacity, and release rate were calculated at certain time points. Moreover, the nanoparticles' optimal formulation and cytotoxic effects were determined using the MTT assay.

resultsThe optimized nanoparticle formulation increases cell death induction in various cancerous cell lines. Moreover, chitosan nanoparticles loaded with

conclusionIt is proposed that this formulation may act as a suitable candidate for more extensive assessments of cancer treatment using nanotechnology-based drug delivery systems.

Indexed as

Antineoplastic AgentsCell SurvivalChitosanDrug Screening Assays, AntitumorNanoparticlesAnimalsCell Line, TumorCell ProliferationDose-Response Relationship, DrugEchisHumansMolecular StructureParticle SizePolyphosphatesStructure-Activity RelationshipVenomous SnakesAntineoplastic AgentsChitosanPolyphosphatestriphosphoric acidViper Venomsanticancer activitychitosanEchis carinatusnanoparticlenanoparticles.tripolyphosphate

Identifiers

PMID38243949
OpenAlexW4391067939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.